(VRTX) Vertex Pharmaceuticals - Ratings and Ratios
Cystic Fibrosis, Sickle Cell, Beta Thalassemia, Acute Pain, Kidney Disease
VRTX EPS (Earnings per Share)
VRTX Revenue
Description: VRTX Vertex Pharmaceuticals September 25, 2025
Vertex Pharmaceuticals (NASDAQ:VRTX) is a Boston-based biotech focused on cystic fibrosis (CF) therapeutics, commercializing a suite of CFTR modulators-including TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO-that together address over 90 % of the U.S. CF patient population across age groups.
The company’s pipeline extends beyond CF to rare-disease and metabolic indications: CASGEVY for sickle-cell disease and transfusion-dependent β-thalassemia (Phase III pending FDA review), JOURNAVX for acute adult pain, VX-522 (CFTR mRNA therapy, Phase 1/2), inaxaplin for APOL1-mediated kidney disease (Phase 2), VX-880/VX-264 for type 1 diabetes, VX-670 for myotonic dystrophy type 1, and VX-407 for autosomal dominant polycystic kidney disease.
Vertex distributes its products through specialty pharmacies, specialty distributors, retail pharmacies, hospitals, and clinics in the United States, and maintains strategic collaborations with CRISPR Therapeutics, Moderna, and Entrada Therapeutics to accelerate gene-editing and mRNA platforms.
Key financial and market drivers: FY 2023 revenue reached approximately $9.0 billion, with ~71 % derived from the CF franchise; the company held a cash and short-term investment balance of $5.5 billion, providing runway for pipeline expansion; the global CF market is projected to grow at a CAGR of ~7 % through 2030, supporting continued demand for Vertex’s modulators.
For a deeper dive into Vertex’s valuation metrics and scenario analysis, the ValueRay platform offers a useful toolkit.
VRTX Stock Overview
| Market Cap in USD | 108,040m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1991-07-24 |
VRTX Stock Ratings
| Growth Rating | 19.6% |
| Fundamental | 86.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -26.1% |
| Analyst Rating | 3.85 of 5 |
VRTX Dividends
Currently no dividends paidVRTX Growth Ratios
| Growth Correlation 3m | 40% |
| Growth Correlation 12m | -51.1% |
| Growth Correlation 5y | 92.1% |
| CAGR 5y | 10.53% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.36 |
| CAGR/Mean DD 3y (Pain Ratio) | 1.44 |
| Sharpe Ratio 12m | 0.71 |
| Alpha | -21.62 |
| Beta | 0.431 |
| Volatility | 23.11% |
| Current Volume | 1261.8k |
| Average Volume 20d | 1273.2k |
| Stop Loss | 407.5 (-3%) |
| Signal | -0.44 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (3.64b TTM) > 0 and > 6% of Revenue (6% = 685.1m TTM) |
| FCFTA 0.15 (>2.0%) and ΔFCFTA 21.35pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 55.08% (prev 52.20%; Δ 2.88pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.16 (>3.0%) and CFO 3.85b > Net Income 3.64b (YES >=105%, WARN >=100%) |
| Net Debt (-3.44b) to EBITDA (4.67b) ratio: -0.74 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.52 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (258.9m) change vs 12m ago 0.31% (target <= -2.0% for YES) |
| Gross Margin 86.11% (prev 86.44%; Δ -0.33pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 51.71% (prev 51.33%; Δ 0.37pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 258.2 (EBITDA TTM 4.67b / Interest Expense TTM 17.0m) >= 6 (WARN >= 3) |
Altman Z'' 6.29
| (A) 0.26 = (Total Current Assets 10.43b - Total Current Liabilities 4.14b) / Total Assets 24.04b |
| (B) 0.47 = Retained Earnings (Balance) 11.29b / Total Assets 24.04b |
| (C) 0.20 = EBIT TTM 4.39b / Avg Total Assets 22.08b |
| (D) 1.63 = Book Value of Equity 11.19b / Total Liabilities 6.86b |
| Total Rating: 6.29 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 86.35
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 3.39% = 1.70 |
| 3. FCF Margin 30.65% = 7.50 |
| 4. Debt/Equity 0.09 = 2.50 |
| 5. Debt/Ebitda -0.74 = 2.50 |
| 6. ROIC - WACC (= 14.01)% = 12.50 |
| 7. RoE 22.14% = 1.85 |
| 8. Rev. Trend 96.76% = 7.26 |
| 9. EPS Trend -18.92% = -0.95 |
What is the price of VRTX shares?
Over the past week, the price has changed by +0.26%, over one month by +6.29%, over three months by -8.82% and over the past year by -11.80%.
Is Vertex Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VRTX is around 405.02 USD . This means that VRTX is currently overvalued and has a potential downside of -3.61%.
Is VRTX a buy, sell or hold?
- Strong Buy: 14
- Buy: 4
- Hold: 14
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the VRTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 480.8 | 14.4% |
| Analysts Target Price | 480.8 | 14.4% |
| ValueRay Target Price | 447.6 | 6.5% |
VRTX Fundamental Data Overview October 27, 2025
P/E Trailing = 29.9495
P/E Forward = 20.9205
P/S = 9.4616
P/B = 6.1032
P/EG = 0.5801
Beta = 0.431
Revenue TTM = 11.42b USD
EBIT TTM = 4.39b USD
EBITDA TTM = 4.67b USD
Long Term Debt = 1.53b USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 92.3m USD (from shortTermDebt, last fiscal year)
Debt = 1.53b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.44b USD (from netDebt column, last quarter)
Enterprise Value = 103.19b USD (108.04b + Debt 1.53b - CCE 6.38b)
Interest Coverage Ratio = 258.2 (Ebit TTM 4.39b / Interest Expense TTM 17.0m)
FCF Yield = 3.39% (FCF TTM 3.50b / Enterprise Value 103.19b)
FCF Margin = 30.65% (FCF TTM 3.50b / Revenue TTM 11.42b)
Net Margin = 31.86% (Net Income TTM 3.64b / Revenue TTM 11.42b)
Gross Margin = 86.11% ((Revenue TTM 11.42b - Cost of Revenue TTM 1.59b) / Revenue TTM)
Gross Margin QoQ = 86.25% (prev 86.90%)
Tobins Q-Ratio = 4.29 (Enterprise Value 103.19b / Total Assets 24.04b)
Interest Expense / Debt = 0.24% (Interest Expense 3.70m / Debt 1.53b)
Taxrate = 19.49% (250.1m / 1.28b)
NOPAT = 3.53b (EBIT 4.39b * (1 - 19.49%))
Current Ratio = 2.52 (Total Current Assets 10.43b / Total Current Liabilities 4.14b)
Debt / Equity = 0.09 (Debt 1.53b / totalStockholderEquity, last quarter 17.18b)
Debt / EBITDA = -0.74 (Net Debt -3.44b / EBITDA 4.67b)
Debt / FCF = -0.98 (Net Debt -3.44b / FCF TTM 3.50b)
Total Stockholder Equity = 16.43b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.13% (Net Income 3.64b / Total Assets 24.04b)
RoE = 22.14% (Net Income TTM 3.64b / Total Stockholder Equity 16.43b)
RoCE = 24.45% (EBIT 4.39b / Capital Employed (Equity 16.43b + L.T.Debt 1.53b))
RoIC = 21.51% (NOPAT 3.53b / Invested Capital 16.43b)
WACC = 7.50% (E(108.04b)/V(109.57b) * Re(7.60%) + D(1.53b)/V(109.57b) * Rd(0.24%) * (1-Tc(0.19)))
Discount Rate = 7.60% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -0.38%
[DCF Debug] Terminal Value 76.70% ; FCFE base≈3.50b ; Y1≈3.16b ; Y5≈2.73b
Fair Price DCF = 192.6 (DCF Value 49.38b / Shares Outstanding 256.4m; 5y FCF grow -12.03% → 3.0% )
EPS Correlation: -18.92 | EPS CAGR: -8.69% | SUE: -0.82 | # QB: 0
Revenue Correlation: 96.76 | Revenue CAGR: 9.08% | SUE: 0.77 | # QB: 0
Additional Sources for VRTX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle